Please login to the form below

Not currently logged in
Email:
Password:

Kadcyla

This page shows the latest Kadcyla news and features for those working in and with pharma, biotech and healthcare.

NICE relents on Kadcyla after Roche pricing negotiations

NICE relents on Kadcyla after Roche pricing negotiations

NICE relents on Kadcyla after Roche pricing negotiations. HER2-positive breast cancer therapy to be made available on the NHS in England. ... Roche has offered an undisclosed price cut which means that around 1, 200 women with incurable secondary breast

Latest news

More from news
Approximately 14 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Positive disruption in business intelligence Positive disruption in business intelligence

    Take the recent recommendation by NICE, the UK’s drug-spending policymaker, of Kadcyla, the breast cancer treatment launched by Roche. ... In December 2016, NICE issued draft guidance indicating Kadcyla was too expensive for routine funding on the NHS.

  • Back to the future Back to the future

    and Kadcyla.

  • Pharma deals during August 2013 Pharma deals during August 2013

    Proof-of-concept has been established with Genentech's Kadcyla currently marketed in the US.

  • Pharma deals during April 2013 Pharma deals during April 2013

    This passion has seemingly been ignited further by the recent FDA approvals of Kadcyla (Genentech/ ImmunoGen) and Adcetris (Seattle Genetics) both following impressive clinic trials in HER2 breast cancer and lymphoma,

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics